Project Grant R43CA298411
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, EE. UU.
Similar Awards
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Aerocytek, Inc. to develop an innovative approach for point-of-care autologous CAR-T cell manufacturing. The project aims to overcome current challenges in large-scale production and integration of CAR-T cell therapies by leveraging targeted microbubble-based technologies for T cell selection, activation, and transduction. This solution seeks to democratize the...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University totals $170,376.00 and is focused on developing a rapid, label-free, and cost-effective technique for Chimeric Antigen Receptor (CAR) T cell quantification in patient blood using Surface Enhanced Raman Spectroscopy (SERS) and Machine Learning (ML). The key products and services to be delivered under this award include: Optimizing a SERS...
- This federal Project Grant award of $1,340,987 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel CAR-enhancer platform. The platform seeks to augment the functionality and longevity of CAR T-cells, addressing the key challenge of limited durability of response in patients. The specific objectives of this 24-month project are to: 1) Optimize dosing and timing for administering the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This $1,124,607 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a Phase 2 multi-center clinical trial of a novel CD5 chimeric antigen receptor (CAR) T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The grant, awarded from July 1, 2025 to June 30, 2027, will validate the safety and efficacy of the improved MB-105 product, which has demonstrated promising results in...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- This $314,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Persistence Therapeutics, Inc.'s novel "SynthNode" approach for CAR T cell therapy. The SynthNode is an implantable device the size of a dime that mimics the function of a lymph node, producing potent, antigen-specific CAR T cells that persist long-term for improved patient outcomes. This fast-track Phase I/II project will complete prototyping,...